Buzz
Searching for COVID-19 information online often leads you through a tangled web of facts, theories, and outright falsehoods. It’s essential to begin with reliable sources and understand their perspectives, rather than assuming everything you encounter is credible. Misinformation is rampant, often spread by conspiracy theorists or individuals driven by political motives rather than scientific evidence. These sources can skillfully disguise weak arguments as authoritative research.
A similar situation occurred with Plandemic: a misleading assortment of falsehoods presented with polished production quality and the appearance of a credible documentary. Many who shared it likely didn’t verify its authenticity, as it seemed legitimate at first glance.
A comparable trend is emerging with other fake 'studies,' such as one promoting hydroxychloroquine that has circulated on social media and even appeared on Fox News. The site hcqtrial.com is not an actual study but is cleverly designed to mimic one.
What’s even more deceptive is how it appropriates scientific terminology and intentionally misapplies it. Although the wording has been adjusted following backlash, the site once asserted it detailed a “country-randomized trial” involving billions of individuals.
Randomized trials are valuable, and larger ones typically yield better results. If someone had genuinely executed, as the site claims, “a massive trial with 2.0 billion participants in the treatment group and 663 million in the control group,” it would represent an extraordinary and costly endeavor.
However, no such trial was ever conducted.
So, what exactly is this so-called study?
As numerous qualified epidemiologists have noted, the creators of this study merely examined COVID-19 mortality rates in a select few countries and inferred that those endorsing hydroxychloroquine usage experienced fewer deaths.
This isn’t a randomized trial involving billions of participants; it’s a backward glance at a limited set of data points (each country analyzed has a death rate and a binary status on hydroxychloroquine usage).
In contrast, a randomized trial involves the researchers assigning participants to groups randomly, ensuring no personal choice or external factors like demographics influence the grouping.
In these countries, individuals could decide whether to take the drug, and governments could determine whether to establish policies or recommendations about it. There’s no randomness here. The study’s flaws are extensive, and detailed critiques are available from experts like epidemiologist Gideon Meyerowitz-Katz and biologist Carl Bergstrom—the latter of whom literally wrote the book on debunking false claims. (This study is a prime example of such claims.)
Why invest so much effort into fabricating a study about hydroxychloroquine?
The website meticulously mimics a scientific publication, but it falls short in several critical areas:
Publishing it in a platform where scientists share their work (even preprint servers, designed for early-stage research discussions)
The authors’ identities
Hydroxychloroquine has become heavily politicized. Among the hundreds of drugs tested on COVID-19 patients this year, as anyone versed in drug development would expect, most have proven ineffective. However, there are a few standout exceptions: Remdesivir appears to hinder viral replication, and dexamethasone has shown promise in improving survival rates for critically ill patients. These findings are encouraging!
Collecting data on hydroxychloroquine wouldn’t be unusual if the drug hadn’t consistently failed in well-structured trials aimed at determining its efficacy. Could there still be a scenario where it aids in combating COVID-19? Possibly, but the likelihood is diminishing rapidly. As Meyerowitz-Katz notes:
Hydroxychloroquine
likely has no effect
on coronavirus. It
fails to assist
those with severe symptoms. It
doesn’t protect
high-risk populations. There’s
no proof
it benefits individuals with mild cases either,
even when paired with azithromycin
. The possibility that HCQ might lower infection risk for low-risk individuals remains uncertain, but
early findings are discouraging
.
You can interpret these results as you wish, but it’s important to recognize the significance of these trials. Conducting a well-controlled randomized study involving over a thousand participants in under six months is a remarkable achievement. The conclusions are clear and unequivocal: HCQ likely offers no benefit for COVID-19 and could potentially cause harm.
If you lack a scientific background, there’s no need to scrutinize a fake scientific document for logical or factual errors. Instead, approach anonymous studies with skepticism, be wary of those aggressively pushing their personal theories, and always cross-reference reliable sources to verify claims. Don’t assume that polished visuals and professional formatting automatically equate to scientific validity.
